Literature DB >> 1279972

Cyclooxygenase products do not modulate angiotensin II-induced contractions of human chorionic plate arteries.

G Sorokin1, N M Grant, B M Egan, J H Lombard.   

Abstract

OBJECTIVE: This study sought to determine whether cyclooxygenase products modulate angiotensin II-induced contractions of human placental arteries. STUDY
DESIGN: Ring segments of chorionic plate arteries (3 to 5 mm inner diameter) were obtained after normal vaginal deliveries. Active force in response to 10(-6) mol/L angiotensin II or 10(-4) mol/L arachidonic acid was measured in the presence or absence of 10(-6) mol/L indomethacin to inhibit cyclooxygenase. The response of K+ contracted arteries to the stable prostacyclin analog iloprost was also tested to determine whether prostacyclin relaxes these vessels. Statistical differences were assessed by analysis of variance, Wilcoxon sign rank test, or Student t test with Bonferroni correction for multiple comparisons.
RESULTS: Successive applications of angiotensin II produced significantly less contraction than the original dose (angiotensin II tachyphylaxis). Angiotensin II tachyphylaxis was unaffected by indomethacin. Arachidonic acid caused an indomethacin-sensitive contraction and iloprost failed to relax the arteries.
CONCLUSIONS: These results suggest that cyclooxygenase products do not mediate angiotensin II tachyphylaxis in these vessels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279972     DOI: 10.1016/s0002-9378(11)91639-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Caveolin-1 prevents sustained angiotensin II-induced resistance artery constriction and obesity-induced high blood pressure.

Authors:  Istvan Czikora; Attila Feher; Rudolf Lucas; David J R Fulton; Zsolt Bagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-19       Impact factor: 4.733

2.  High intraluminal pressure via H2O2 upregulates arteriolar constrictions to angiotensin II by increasing the functional availability of AT1 receptors.

Authors:  Zsolt Bagi; Nora Erdei; Akos Koller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.